Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3
- PMID: 9873005
- DOI: 10.1074/jbc.274.2.703
Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3
Abstract
An alternatively spliced variant of Smad2 with a deletion of exon 3 (Smad2Deltaexon3) is found in various cell types. Here, we studied the function of Smad2Deltaexon3 and compared it with those of wild-type Smad2 containing exon 3 (Smad2(wt)) and Smad3. When transcriptional activity was measured using the p3TP-lux construct, Smad2Deltaexon3 was more potent than Smad2(wt), and had activity similar to Smad3. Transcriptional activation of the activin-responsive element (ARE) of Mix.2 gene promoter by Smad2Deltaexon3 was also similar to that by Smad3, and slightly less potent than that by Smad2(wt). Phosphorylation by the activated transforming growth factor-beta type I receptor and heteromer formation with Smad4 occurred to similar extents in Smad2Deltaexon3, Smad2(wt), and Smad3. However, DNA binding to the activating protein-1 sites of p3TP-lux was observed in Smad2Deltaexon3 as well as in Smad3, but not in Smad2(wt). In contrast, Smad2(wt), Smad2Deltaexon3, and Smad3 efficiently formed ARE-binding complexes with Smad4 and FAST1, although Smad2(wt) did not directly bind to ARE. These results suggest that exon 3 of Smad2 interferes with the direct DNA binding of Smad2, and modifies the function of Smad2 in transcription of certain target genes.
Similar articles
-
Smad2Δexon3 and Smad3 have distinct properties in signal transmission leading to TGF-β-induced cell motility.J Biol Chem. 2023 Feb;299(2):102820. doi: 10.1016/j.jbc.2022.102820. Epub 2022 Dec 20. J Biol Chem. 2023. PMID: 36549646 Free PMC article.
-
The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.Kidney Int. 1999 Oct;56(4):1354-65. doi: 10.1046/j.1523-1755.1999.00680.x. Kidney Int. 1999. PMID: 10504488
-
Smad3 inhibits transforming growth factor-beta and activin signaling by competing with Smad4 for FAST-2 binding.J Biol Chem. 1999 Oct 29;274(44):31229-35. doi: 10.1074/jbc.274.44.31229. J Biol Chem. 1999. PMID: 10531318
-
Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus.Mol Cell Biol. 2000 Dec;20(23):9041-54. doi: 10.1128/MCB.20.23.9041-9054.2000. Mol Cell Biol. 2000. PMID: 11074002 Free PMC article.
-
Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta.EMBO J. 2000 Oct 2;19(19):5178-93. doi: 10.1093/emboj/19.19.5178. EMBO J. 2000. PMID: 11013220 Free PMC article.
Cited by
-
Transcriptional Control by the SMADs.Cold Spring Harb Perspect Biol. 2016 Oct 3;8(10):a022079. doi: 10.1101/cshperspect.a022079. Cold Spring Harb Perspect Biol. 2016. PMID: 27449814 Free PMC article. Review.
-
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.Am J Pathol. 2004 Jul;165(1):203-17. doi: 10.1016/s0002-9440(10)63289-0. Am J Pathol. 2004. PMID: 15215176 Free PMC article.
-
miR-192 mediates TGF-beta/Smad3-driven renal fibrosis.J Am Soc Nephrol. 2010 Aug;21(8):1317-25. doi: 10.1681/ASN.2010020134. Epub 2010 May 20. J Am Soc Nephrol. 2010. PMID: 20488955 Free PMC article.
-
TGF-β and restenosis revisited: a Smad link.J Surg Res. 2011 May 15;167(2):287-97. doi: 10.1016/j.jss.2010.12.020. Epub 2011 Jan 15. J Surg Res. 2011. PMID: 21324395 Free PMC article. Review.
-
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel). 2024 Apr 20;17(4):533. doi: 10.3390/ph17040533. Pharmaceuticals (Basel). 2024. PMID: 38675493 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous
